Fosun Pharmaceutical announced that its holding subsidiary Shanghai Yuji Health Technology Co., Ltd. has received approval from the US FDA to allow LBP-shc4 to conduct clinical trials, and plans to conduct phase I clinical trials after conditions are met. LBP-shc4 is a live biological therapy product independently developed by Fosun Pharmaceutical. It is intended to treat androgenic alopecia. As of April 2025, Fosun Pharmaceutical's cumulative R&D investment for LBP-ShC4 was approximately RMB 17 billion. As of the announcement date, no live biotherapy products used to treat androgenic alopecia have been approved for marketing in the world. Drug development and marketing is a long-term process, and there are many uncertainties.

Zhitongcaijing · 05/09 08:25
Fosun Pharmaceutical announced that its holding subsidiary Shanghai Yuji Health Technology Co., Ltd. has received approval from the US FDA to allow LBP-shc4 to conduct clinical trials, and plans to conduct phase I clinical trials after conditions are met. LBP-shc4 is a live biological therapy product independently developed by Fosun Pharmaceutical. It is intended to treat androgenic alopecia. As of April 2025, Fosun Pharmaceutical's cumulative R&D investment for LBP-ShC4 was approximately RMB 17 billion. As of the announcement date, no live biotherapy products used to treat androgenic alopecia have been approved for marketing in the world. Drug development and marketing is a long-term process, and there are many uncertainties.